1. Refractory Lymphocytic Enterocolitis and Tumor Necrosis Factor Antagonist Therapy 
Ghazaleh Aram, Theodore M. Bayless, Zong–Ming Chen, Elizabeth A. Montgomery, Mark Donowitz, Francis M. Giardiello 
Clinical Gastroenterology and Hepatology 
Volume 8, Issue 4, Pages (April 2010)
DOI: /j.cgh
Copyright © 2010 AGA Institute Terms and Conditions

2. Figure 1
Case 1. Small-bowel biopsy (A) before and (B) after treatment. (A) Marked villous blunting, intraepithelial lymphocytosis, and increased mixed inflammation in the lamina propria. (B) Tumor necrosis antagonist therapy resulted in normal-appearing villi with mildly increased intraepithelial lymphocyte infiltration. Colonic biopsy (C) before and (D) after treatment. (C) Marked intraepithelial lymphocytosis and mixed inflammation in the lamina propria. (D) Normal-appearing colonic mucosa with mildly increased intraepithelial lymphocyte inflammation.
Clinical Gastroenterology and Hepatology 2010 8, DOI: ( /j.cgh )
Copyright © 2010 AGA Institute Terms and Conditions

3. Figure 2
Immunohistochemical staining of lymphocytic cellular infiltrate (A) positive for CD3 (T-cell marker), (B) negative for CD20 (B-cell marker), (C) positive for CD8 (suppressor cell marker), and (D) negative for CD 4 (helper cell marker).
Clinical Gastroenterology and Hepatology 2010 8, DOI: ( /j.cgh )
Copyright © 2010 AGA Institute Terms and Conditions